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Abstract: Tremendous efforts have been made these last decades to increase our knowledge of
intracellular degradative systems, especially in the field of autophagy. The role of autophagy in the
maintenance of cell homeostasis is well documented and the existence of defects in the autophagic
machinery has been largely described in diseases and aging. Determining the alterations occurring in
the many forms of autophagy that coexist in cells and tissues remains complicated, as this cellular
process is highly dynamic in nature and can vary from organ to organ in the same individual.
Although autophagy is extensively studied, its functioning in different tissues and its links with
other biological processes is still poorly understood. Several assays have been developed to monitor
autophagy activity in vitro, ex vivo, and in vivo, based on different markers, the use of various
inhibitors and activators, and distinct techniques. This review emphasizes the methods applied to
measure (macro-)autophagy in tissue samples and in vivo via a protein, which centrally intervenes in
the autophagy pathway, the microtubule-associated protein 1A/1B-light chain 3 (MAP1LC3), which is
the most widely used marker and the first identified to associate with autophagosomal structures.
These approaches are presented and discussed in terms of pros and cons. Some recommendations are
provided to improve the reliability of the interpretation of results.
Keywords: autophagy; autophagic flux; MAP1LC3; lysosome; in vivo autophagy assays
1. Introduction
Autophagy (from the ancient Greek “αὐτóϕαγoς”, meaning “self-eating”) is a critical component
of cell homeostasis. This pivotal process contributes to the cellular quality control and energetic
regulation of tissues via the lysosomal processing and recycling of vital cellular components [1]. Three
main forms of autophagy are classically described that are macroautophagy, microautophagy, and
chaperone-mediated autophagy (CMA), but in fact, there are many more forms and subtypes of each
(as the different types of microautophagy, for example), working concomitantly in the cell to control
its viability. Some of these processes are highly selective, some others are less, but all share a certain
degree of selectivity to mediate the degradation of specific targets [2–6].
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Much autophagic research has been originally done by exploiting organisms such as the versatile
yeast and drosophila, and then followed by mammals. Over the past decades, significant advances
have been made, leading to a better understanding of the molecular mechanisms driving autophagy in
its many intricate physiological functions. These activities are thought to be particularly important
in all aspects of cell life including differentiation and development, adaptation to metabolic stresses,
degradation of dangerous cargo (e.g., misfolded or aggregated proteins, proteins produced daily
in excess, damaged organelles, intracellular pathogens), and regulation of immune responses.
It occurs, however, that these normally protective functions become harmful when autophagy
processes are altered. Recent studies centered on the molecular biology of autophagy have especially
addressed these issues in diseases as diverse as autoimmune and inflammatory syndromes, cancer,
neurodegeneration, infectious diseases, cardiovascular disorders, metabolic diseases, intestinal bowel
diseases, ischemia–reperfusion injury, and aging [5,7–12]. Mutations in numerous autophagy-related
(ATG) genes have been linked to specific diseases, although rarely to one single pathology [4]. These
mutations affect the proper functioning and regulation of autophagy and lysosomal activity, as well as
cargo delivery. Their consequences also interfere in the crosstalk of autophagy with the many other
forms of cellular circuits, such as apoptosis, necrosis, and ferroptosis [6].
These last years, the molecular elements of autophagy pathways characterizing macroautophagy,
CMA, and more recently endosomal microautophagy (eMI), have been extensively studied. The cascade
of events giving rise to the coordinated emergence of diversified organelles, the implication of multiple
ATG genes, the identification of proteins complexes, for example, the ULK1 serine–threonine kinase
(involving ULK1, FIP200, ATG13, and ATG101) and the VPS34/BECLIN-1 (BECN1) complex, which
act sequentially in the autophagic processes, have been precisely examined [4,13–16]. These studies
have permitted to pinpoint a number of markers that characterize different steps or forms of the
autophagy process [17]. The combined use of drugs acting as activators or inhibitors on selected
components and of genetically manipulated eukaryotic models have greatly contributed to the
identification of successive steps and key components of the main autophagic pathways [14,18].
Particular attention should be given when certain drugs (e.g., bafilomycin A1) are used experimentally
as their effect can critically depend on the time and concentration used as well as on the cell type. These
drugs have also allowed demonstrating the potential interest of targeting autophagy for therapeutic
applications [7,9,17]. Examples of such pharmacological agents and their main mechanism of action
are listed in Table 1. Several comprehensive reviews extensively document their effects and some of
their limitations [4,7,9,10,17–22].
Table 1. Examples of autophagic and lysosomal activators and inhibitors (non-exhaustive list) 1.
Autophagy Activators Mechanism of Action
KU-0063794 Inhibits MTORC1 and MTORC2
Lithium, carbamezapine, sodium valproate Reduces intracellular inositol levels by inhibitingtheir synthesis
Metformin Activates AMPK
NVP-BEZ235 Inhibits PI3K/MTOR
Rapamycin, everolimus, temsirolimus (CCI-779),
deforolimus, AZD8055
Interact wih FkBP-12 and the complex inhibits the
activity of MTOR
Resveratrol Activates SIRT1
Spermidine Inhibits several acetyltransferases, e.g., EP300, IKI3,and SAS3
Statins (simvastatin) Inhibits PKB/AKT
Sucrose Impairs lysosomal function
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Table 1. Cont.
Autophagy Activators Mechanism of Action
Tamoxifen Increases the intracellular level of ceramide.Abolishes the inhibitory effect of PI3K
TAT-Beclin-1
Inhibits the activity of PI3KC3 through competing of
the binding of BECN1 to its negative regulator
GAPR-1
Torkinib (PP242), torin 1 Inhibits MTORC1/2
Trehalose Impairs lysosomal function
Tunicamycin Induces ER stress in cells by inhibiting the first step ofthe biosynthesis of N-linked glycans in the proteins
Autophagy Inhibitors Mechanism of Action
Azithromycin Inhibits lysosomal v-ATPase and prevents theacidification process
Bafilomycin A1, concanamycin A
Both specifically bind to the V0 domain of v-ATPase
and inhibit the intracellular pH gradients in endocytic
and secretory organelles
CQ/HCQ Increases the lysosomal pH (v-ATPase-independent)
Colchicine, Lys05, monensin, nigericine, nocodazole,
SAHA (vorinostat), vinblastine Inhibits autophagosome-lysosome fusion
E64d/pepstatin A Inhibits cysteine and aspartic proteases
Leupeptin Inhibits serine and cysteine proteases
NH4Cl Increases the lysosomal pH (v-ATPase-independent)
P140 peptide Inhibits the chaperone activity of HSPA8
Wortmannin, 3-methyladenine, LY294002 Inhibits class III PI3K
See abbreviations in the abbreviations section. 1 For more information, including their chemical structures, refer to
the reviews [7,17–25].
Discovered in our team, a 21-mer phosphopeptide called P140, which primarily targets CMA
in vitro and ex vivo and corrects altered macroautophagy occurring in inflammatory pathological
contexts, showed its therapeutic effectiveness both in animal models of autoimmunity [26–30]
and in patients with lupus [31,32]. Given to lupus mice with active disease, P140 reduced the
overexpression level of lysosomal-associated membrane protein (LAMP)2A and HSPA8, two key
players of CMA [33–35]. In vitro, P140 inhibited CMA in a cell line that stably expressed a CMA
reporter [34,35]. In NOD.H-2h4 mice that develop a primary Sjögren’s-like syndrome, P140 rescued sick
mice from some autophagy defects presumably associated with the ULK1 complex, and significantly
reduced the formation of tertiary lymphoid structures in salivary glands, a hallmark characteristic of
this disease in patients [30]. The expression of BECN1, which was raised in diseased NOD.H-2h4 mice,
a feature that could explain, at least in part, the clinical and biological beneficial effect of P140 in this
mouse model.
Another peptide, the cell-penetrating peptide Tat-BECN1, rather acts as an activator of
autophagy [36]. It was found to exert protection against viral and bacterial infection both in vitro and
in vivo, and some effectiveness in other pathological conditions such as heart failure in response to
cardiac hypertrophy, for example [4]. The activity of some rationally-designed analogs of Tat-BECN1
peptide, like Tat-D11 (Novus Biologicals), prove significantly more potent than the original sequence
in different assays and indications. A peptide named humanin initially identified from surviving
neurons in patients with Alzheimer’s disease (AD), was described as a direct enhancer of CMA
that acts by increasing substrate binding and translocation into lysosomes [37]. It interacts with
HSP90 and stabilizes the binding of this chaperone to CMA cargos as they bind to the lysosomal
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membrane. It was shown that humanin exerts cardioprotective and neuroprotective properties in
diseases such as AD, cardiovascular diseases, stroke, myocardial infarction, diabetes, and cancer. These
peptides and other molecules that target specific autophagy elements represent potential therapeutics
that might be successfully applied to treat patients affected by pathologies for which current drugs
are clearly insufficient with severe secondary effects, or to individuals who are refractory to the
existing medications.
When developing new chemical strategies of intervention that target autophagy, an important step
is to demonstrate that in vivo, and not only in vitro or ex vivo, the molecule is effective on the expected
autophagic target that has been identified in the upstream investigations. Indeed, in vivo, it may well
be that the molecule induces its effect as thought, i.e., directly on the expected autophagy component
but it might also act via an autophagy-independent mechanism or on an alternative metabolic system
that in fine impact autophagy. It is effectively well known that numerous autophagy-related markers
are also involved in other metabolic pathways. It is the case of BECN1, HSPA8, MTOR, and many
others [4,23]. Yet, measuring autophagy in vivo or even in tissue samples (biopsies) collected from
patients, for example, remains a challenge. Assessment of autophagic flux in whole organisms is even
more challenging. Specific assays are limited and often remain non validated given the variety of tissues
and organisms that are studied. The aim of this review is to gather useful information compiled from the
existing literature and generated by our own experience, to analyze the validity of proposed methods
and to discuss their potential and limitations. An emphasis is placed on microtubule-associated
protein 1A/1B-light chain 3 (MAP1LC3) that is central in the autophagy process and especially in
macroautophagy. Present at low and variable levels of expression in a normal situation, its distribution
is widespread, for example in the bone marrow, brain, heart, placenta, thyroid, bladder, and several
other organs and tissues.
2. The Microtubule-Associated Protein 1A/1B-Light Chain 3 (MAP1LC3)
Together with sequestosome (SQSTM1)/p62, MAP1LC3 is the most widely used marker that
is followed experimentally to evaluate the extent of autophagy in cells. MAP1LC3 is a member
of the highly conserved ATG8 protein family. It was initially described in the yeast (S. cerevisiae)
and later identified in mammals [38,39]. MAP1LC3 belongs to a large family of seven members
composed of MAP1LC3A, 3B, 3B2, 3C, and the γ-aminobutyric acid (GABA)-receptor-associated
proteins (GABARAP, GABARAPL1, GABARAPL2) proteins. The NMR structure of MAP1LC3B
(residues 1-120) has been determined (Figure 1) [40]. The members of this protein family share a
common ubiquitin-like (Ubl) structures present at the C-terminus and twoα-helices at their N-terminus,
which are likely involved in protein–protein and lipid–protein interactions and post-translational
modifications that occur during the autophagy process [41–44]. In the cytosol, newly synthesized
MAP1LC3B is cleaved by the autophagy-related 4B cysteine peptidase (ATG4B) at the C-terminal
glycine residues120 leading to MAP1LC3-I (Figure 1). Phosphatidylethanolamine (PE)-conjugation
of MAP1LC3-I resulting in the lipidated MAP1LC3-II form requires ATG7 and ATG3, as well as the
ATG12–ATG5–ATG16L1 complex [45–47]. Formation of the latter involves conjugation of ATG12
to ATG5, in a process mediated by ATG7 and ATG10, and further binding of the ATG12–ATG5
conjugate to an ATG16L1 dimer. In this process, ATG7 plays a central role as this E1-like activating
enzyme enables both the lipidation of ATG8 proteins (MAP1LC3) and conjugation of ATG12 to
ATG5. It is the only enzyme common to both conjugation pathways. At the isolation membrane
and autophagosomes, MAP1LC3-II displays significant functions in the autophagy process, such as
elongation, sealing isolation membranes, recognizing cargos, etc. [47]. The Ubl structures encompass
β-strands with hydrophobic pockets, which are implicated in protein interactions. MAPL1LC3 is
also present in the nucleus of a variety of cell types. In response to starvation, nuclear MAP1LC3
is deacetylated and trafficked out of the nucleus into the cytoplasm where it exerts its functions in
autophagy. The protein is also enriched in nucleoli where it binds nuclear and nucleolar constituents,
such as microtubule-associated protein 1B, tubulin, and ribosomal proteins.
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Figure 1. Structure of MAP1LC3B. The protein presents as a monomer with a molar mass of 13.6 kDa. 
(A) Pictorial illustration showing the alignment of α-helices and β-sheets in LC3B. (B) Primary 
structure of MAP1LC3B (NCBI reference ID: NP_073729.1) showing the positions of α-helixes and β-
sheets. The sites of phosphorylation and acetylation are highlighted in yellow and red, respectively. 
The UbI domain is located at the C-terminus of the protein. (C) Three-dimensional (3D)-structure 
(PDB ID: 1V49) of the MAP1LC3B fragment 1–120. Figure generated using https://www.rcsb.org/, ref. 
doi:10.1093/bioinformatics/bty419. 
MAP1LC3 proteins interact with many cofactors and ligands. All interacting proteins display a 
common ubiquitin-binding domain (UBD) and a short hydrophobic LC3-interacting region (LIR) 
motif that contains an N-terminal sequence W (tryptophan)xxL (leucine). The W residue is 
surrounded by other aromatic residues, tyrosine (Y) and phenylalanine (F), acidic residues, and 
sometimes serine (S) and threonine (T) residues to compose a consensus W/F/YXXL/I/V motif. These 
residues interact with the basic residues present in the Ubl domain of MAP1LC3 via electrostatic 
bridges (Figure 1). LIR motif-containing proteins encompass two hydrophobic residues, which are 
accommodated into the MAP1LC3 binding pockets [48]. The LIR motifs are post-translationally 
regulated and contribute to the different functions displayed by MAP1LC3 proteins, including 
selective autophagy process [48–51]. 
MAP1LC3 plays a key role in the autophagosome biogenesis machinery from the isolation 
membrane to the lysosomal stage. The recruitment of MAP1LC3 and other ATG proteins triggers 
vesicle expansion in a concerted manner and intervenes in the initial steps of membrane curvature. 
During this complex sequential process, MAP1LC3 is finely regulated by diverse post-translational 
modifications, which favor or on the contrary alter its activity. Thus, phosphorylation of MAP1LC3B 
at Thr50 by serine/threonine-protein kinases STK3/STK4 is essential for the autophagosome–
lysosomal fusion process [52]. Phosphorylation at residue Ser12 by phosphokinase A (PKA) keeps 
MAP1LC3B unavailable for conjugation to PE and inhibits the autophagy process [53]. This 
modification is essential for phagophore expansion; its failure leads to defects in autophagosome 
formation. During stress or starvation conditions, PKA activity is inhibited and MAP1LC3B remains 
available for conjugation. On the other hand, acetylation regulates the MAP1LC3B translocation from 
the nucleus to the cytosol. The reason for the presence of LC3B in the nucleus remains an unanswered 
question. Acetylation at residues Lys49 and Lys51 makes the MAP1LC3B protein confined to the 
nucleus and not available for cytosolic ligases [54]. Of note, Lys49 and Lys51 form ionic interactions 
with ligands, especially with the LIR motifs. In stress conditions, especially starvation, deacetylation 
of MAP1LC3B by sirtuin 1 results in the availability of MAP1LC3B for ligases [54]. 
Figure 1. Structure of MAP1LC3B. The protein presents as a monomer with a molar mass of 13.6 kDa.
(A) Pictorial illustration showing the alignment of α-helices and β-sheets in LC3B. (B) Primary
structure of MAP1LC3B (NCBI reference ID: NP_073729.1) showing the positions of α-helixes and
β-sheets. The sites of phosphorylation and acetylation are highlighted in yellow and red, respectively.
The UbI do ain is located at the C-ter inus of the protein. (C) Three-di ensional (3D)-structure
(PDB ID: 1V49) of the MAP1LC3B fragment 1–120. Figure generated using https://www.rcsb.org/, ref.
doi:10.1093/bioinformatics/bty419.
MAP1LC3 proteins interact with many cofactors and ligands. All interacting proteins display a
common ubiquitin-binding domain (UBD) and a short hydrophobic LC3-interacting region (LIR) motif
that contains an N-terminal sequence W (tryptophan)xxL (leucine). The W residue is surrounded by
other aromatic residues, tyrosine (Y) and phenylalanine (F), acidic residues, and sometimes serine (S)
and threonine (T) residues to compose a consensus W/F/YXXL/I/V motif. These residues interact with
the basic residues present in the Ubl domain of MAP1LC3 via electrostatic bridges (Figure 1). LIR
motif-containing proteins encompass two hydrophobic residues, which are accommodated into the
MAP1LC3 binding pockets [48]. The LIR motifs are post-translationally regulated and contribute to the
different functions displayed by MAP1LC3 proteins, including selective autophagy process [48–51].
MAP1LC3 plays a key role in the autophagosome biogenesis machinery from the isolation
membrane to the lysosomal stage. The recruitment of MAP1LC3 and other ATG proteins triggers
vesicle expansion in a concerted manner and intervenes in the initial steps of membrane curvature.
During this complex sequential process, MAP1LC3 is finely regulated by diverse post-translational
modifications, which favor or on the contrary alter its activity. Thus, phosphorylation of MAP1LC3B
at Thr50 by serine/threonine-protein kinases STK3/STK4 is essential for the autophagosome–lysosomal
fusion process [52]. Phosphorylation at residue Ser12 by phosphokinase A (PKA) keeps MAP1LC3B
unavailable for conjugation to PE and inhibits the autophagy process [53]. This modification is essential
for phagophore expansion; its failure leads to defects in autophagosome formation. During stress or
starvation conditions, PKA activity is inhibited and MAP1LC3B remains available for conjugation.
On the other hand, acetylation regulates the MAP1LC3B translocation from the nucleus to the cytosol.
The reason for the presence of LC3B in the nucleus remains an unanswered question. Acetylation at
residues Lys49 and Lys51 makes the MAP1LC3B protein confined to the nucleus and not available for
cytosolic ligases [54]. Of note, Lys49 and Lys51 form ionic interactions with ligands, especially with the
LIR motifs. In stress conditions, especially starvation, deacetylation of MAP1LC3B by sirtuin 1 results
in the availability of MAP1LC3B for ligases [54].
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3. Current MAP1LC3-Based Methods Designed for Autophagy Research
MAP1LC3-based assays are widely used in current autophagy research [22,55–58]. In general, they
offer the possibility to monitor the cellular autophagic activity in a routine manner using conventional
laboratory equipment. A number of advantageous criteria, such as sensitivity, performance, specimen
throughput, volume requirements, the limit of detection, ease of execution, instrument workspace, and
the costs of equipment and disposal, are met. Commonly, the detection of processed MAP1LC3B-II by
Western blot (Figure 2) or fluorescence studies, together with electron microscopy for autophagosome
formation (Figure 3), is sufficient to qualify autophagy in cells.
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These basic methods, applied to primary cells and cell lines, are often adequate for the first series
of screening tests, but they may appear insufficient to further develop knowledge for therapeutic
purposes. Indeed, they suffer each from intrinsic limitations that can introduce errors in the data
analyses and survey results (Table 2). Furthermore, and most importantly, they often apply to cells and
not to tissues and organs and are routinely performed in vitro/ex vivo and not in vivo.
Table 2. MAP1LC31-based standard assay for assessing autophagy and their limitations 1.
Techniques Special Attention, Limitations and Pitfalls
Western blot assay
(Figure 2)
• Examining the expression of MAP1LC3-I and -II in the presence and
absence of protease inhibitors is an absolute requirement 2.
• Certain autophagosome-lysosome fusion competitors inhibit MTORC1,
which initiates the induction of autophagy process [56,61,62].
• The choice of inhibitors is decisive. For example, CQ can activate
MAP1LC3-II formation independently from autophagy [63].
• Specific detection of MAP1LC3-II is dependent on the type of antibody
used. The majority of commercialized antibodies cross-react with several
MAP1LC3 isoforms [64,65].
• Antibodies may show different affinity for MAP1LC3-I and -II, and
together with differing protein stability of the non- and lipidated forms
western blotting bands require careful interpretation.
Fluorescence microscopy
for detecting endogenous
MAP1LC3
• Discrimination between immatured, not yet closed and mature
autophagosomes is required as both appear as punctate.
• Characterization of MAP1LC3 puncta. Advanced image analysis
software’s (e.g., Top Hat algorithm of MetaMorph version 7.0 by
Molecular Devices and G-Count by G-Angstrom) is a very useful tool to
measure MAP1LC3 puncta [56]. Quantification can also be made manually
by a trained and blinded observer.
• Discrimination of true autophagosomes devoid of MAP1LC3 aggregates,
which are formed due to the aggregate prone proteins and
autophagy-independent manner can be difficult.
Fluorescence microscopy
for detecting reporters (e.g.,
GFP-MAP1LC3,
mRFP-GFP-MAP1LC3, . . . )
• Tissues from GFP-MAP1LC3 transgenic mice expresses more
auto-fluorescence punctate structures [66].
• Lack of GFP-MAP1LC3 expression in GFP-MAP1LC3 transgenic mice
brain was observed, unlike other tissues.
• Cells deficient of ATG proteins, especially ATG5, would not generate
MAP1LC3 punctate structures [67]. However, not all MAP1LC3 punctate
structures are indicative of autophagy [58].
• Loss of time-dependent fluorescence (GFP-MAP1LC3) intensity, but not
mutant MAP1LC3, was observed [68].
• In GFP- or mRFP-GFP-MAP1LC3 constructs, labelling may not give
absolute results, especially if the pH of lysosomes is altered in pathological
situations (as in lupus, for example, in which the mean lysosomal pH is
raised [35]).
• Use of samples with or without inhibitors should be maintained for the
better comparison (except for a few probes, e.g.,
GFP-MAP1LC3-RFP-MAP1LC3∆G).
• In terms of GFP-MAP1LC3-RFP-LC3∆G probe, more time (>2 h) is needed
to observe significant changes in fluorescence ratio. Clone selection
(transfection studies) should be monitored [69,70].
• Assays based on the red fluorescent protein Keima cannot be used with
fixed cells because the assay completely relies on lysosomal acidity [71].
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Table 2. Cont.
Techniques Special Attention, Limitations and Pitfalls
Flow cytometry
• Detects the different forms of endogenous MAP1LC3 (incl. MAP1LC3-I,
MAP1LC3-II) proteins without any discrimination.
• Improved speed and statistical power when determining autophagic flux
using tandem MAP1LC3 fusion proteins.
• Requires isolation of subcellular vesicles (e.g., autophagosomes,
lysosomes) to highlight possible defects in the expression of endogenous
MAP1LC3 protein levels [72].
• Necessity to handle cell samples immediately [73].
Multispectral imaging flow
cytometry
• Combines features of flow cytometry with the imaging content of
fluoresecent microscopy [74,75]
• Allows for detection of MAP1LC3 dot formation representative
for MAP1LC3-II.
• Visualization of MAP1LC3 co-localization with lysosomal markers or
other proteins.
Bioluminescence
• Using a luminescent peptide to tag endo- and exogenous MAP1LC3 [76].
• Allows easy detection and sensitive quantification of specific
MAP1LC3 isoforms.
• Adapted to perform high throughput screening of compounds,
for example.
• Small marker peptide allows for facilitated endogenous gene tagging
using CRISPR/Cas9 technology.
• Does not allow detection of MAP1LC3 punctae formation.
MAP1LC3B time-resolved
fluorescence transfer
(TR-FRET) assay
• Homogenous, mix-and-read assay that takes advantage of the required
proximity of the donor and acceptor species for the generation of signal
[77].
Electron microscopy
(Figure 3)
• Difficulty in discriminating the various types of vesicles (autolysosomes,
endosomes, amphisomes, lysosomes)
• Difficulty to evaluate autophagy dynamics.
• No direct information obtained on lysosomal degradation.
• Time consuming.
• Technical errors, e.g., poor-fixation, sometimes leads to over or under
looking observations [78].
• Conventional methods, but not advanced electron microscopy methods,
are not suitable to determine the volume and size of the inner cell
compartments, due to the thin sections [60].
Long-lived protein
degradation
• Proteasome inhibitors should be used to specify the action of autophagy.
• Labelling efficiency is always a question, e.g., special culture media,
without methionine, is required in non-radioactive labelling [79].
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Table 2. Cont.
Techniques Special Attention, Limitations and Pitfalls
LDH sequestration assay • Lysosomal inhibitors always need to be used to measure autophagic flux
[80].
Dextran sequestration
assay
• Loading fluorescently labelled dextran into cells is a delicate operation
[81,82].
1 A few other conventional methods and/or nonspecific methods, such as isotope release from long-lived protein
degradation (radiolabeling long-lived proteins with radioactive amino acid residues, such as [14C]-leucine,
[3H]-leucine, [14C]-valine, or [35S]-methionine) and LDH assay (using LDH as a cargo) are not reviewed here
as they are not routinely used. 2We are well aware that determining the ATG protein levels or the number of
autophagosomes alone does not provide the overall estimation of autophagic activity since the process is very
dynamic, and MAP1LC3-II can quickly degrade within the lysosomes. In fact, the two opposite scenarios, namely
induction of autophagy or blockade in the downstream steps of autophagy leading to defective degradation, can
result in an increased number of autophagosomes. Therefore, it is necessary to evaluate the autophagic flux by
measuring the level of expression of MAP1LC3-I and -II in the presence of lysosomal inhibitors such as bafilomycin
A1 or others. See abbreviations in the abbreviations section.
In general, these methods have the capability for a high sample throughput and are used to sift
large numbers of such samples for further application. As indicated, however, they also have some
disadvantages and intrinsic limitations. The results that are generated to support possible changes in
autophagy processes have also to be distinguished from effects induced by the many other forms of
cell death [22,83].
4. MAP1LC3-Based Methods Designed for Studying Autophagy in Tissues
Several methods have been described to detect MAP1LC3 directly in fresh and fixed tissues
collected from patients and experimental animal models. They are listed in Table 3 with their respective
advantages and limitations (see also the Box 1).
Table 3. MAP1LC3-based methods to measure autophagy in biopsies.
Method Advantages Limitations
Immunohistochemistry
• High throughput analysis of MAP1LC3
localization in tissue arrays.
• Availability of fixed tissues in the clinic.
• Co-localization with additional
autophagy-related proteins can be analyzed.
• Availability of MAP1LC3 isoform
specific antibodies with sufficient
sensitivity for FFPE tissue sections.
• Quantifying MAP1LC3 punctae
needs experienced pathologist.
Western blot analysis
(from FFPE tissue) [84]
• Distinction between MAP1LC3-I and -II.
• A lot of tissue is needed to extract
enough protein.
• Requires protein extraction from a
cell mixture.
• Isolation of pure cell populations
from the tissues would be needed to
analyze cell-specific levels of
MAP1LC3 expression.
• No information on
MAP1LC3 localization.
In-situ hybridization [85]
• Highly specific for MAP1LC3 isoforms.
• Allows to assess MAP1LC3 isoform
expression levels in different cell types.
• MAP1LC3 mRNA expression is not a
“marker” of autophagy activity
per se.
• One needs to assume that MAP1LC3
mRNA levels correlate with
protein expression.
See abbreviations in the abbreviations section.
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Box 1. Central aspects to consider while monitoring autophagy.
General considerations
- Autophagy is a dynamic mechanism that requires flux measurements to be monitored.
- An increase of autophagy markers or factors detected at an early stage of the process may not give a clear
idea on the entire process of autophagy as the blockade may appear at later stages. -Selection of mouse
strain, while transfecting MAP1LC3, is a prominent factor in autophagy research, since for example, basal
autophagy markedly differs between mouse strains.
- Detecting an increasing number of lysosomes may not reflect an increase in autophagic activity. LysoSensor
may help to differentiate between the effects of autophagosome to lysosomes.
- It can be difficult to propose conclusions in some instances, especially in infections, in which the life cycle
of pathogens affects the basal autophagic pathway.
Technical considerations
- Lack of highly specific autophagy inhibitors and activators remains a limiting factor.
- Autophagy-inducing agents, either for autophagy flux measurement or therapy, behave differently upon
time and dosage.
- To evaluate novel molecules on inhibition or activation of autophagy, it is strongly recommended to use
standard controls such as starved conditions and knockdown/knockout of key ATG proteins (e.g., ATG3, 5,
7, 9a, 16L1, FIP200, AMBRA1, BECN1) as a starting point.
- Autophagy modulator screening assays using GFP-MAP1LC3 benefit from secondary probes
(GFP-MAP1LC3-RFP-LC3∆G, mRFP-GFP-MAP1LC3, mCherry-GFP-MAP1LC3) to clearly discriminate
the effects on autophagosomes from effects on lysosomes or autolysosomes.
Specific considerations that apply when organs/tissue are studied
- The autophagic process (type, regulation, intensity) can differ from cell to cell, organ to organ/tissue in the
same individual.
- Many fluorescence methods used in autophagy monitoring require specialized fixation methods, fresh
tissue preparation, and rapid visualization. Most of the classical methods are not applicable in the case of
the brain.
Examples are highlighted in Figure 4 using mouse colonic tissues, and human lung cancer tissues
and cell lines.
A variety of suppliers provide adequate antibodies that should be evaluated and finely
calibrated in each cell/tissue and methodological condition to gain an optimal signal/background ratio.
A non-exhaustive list is given in Table 4.
As indicated, although MAP1LC3-II has been widely used as a marker to detect autophagy in
various tissue samples from patients (biopsies or extraction of tissues at autopsy) or animal models,
these assays cannot provide information on the dynamics of autophagy process and flux.
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Figure 4. Immunofluorescence for MAP1LC3B. (A) Colon tissue sections of a control mouse and a 
mouse treated by TNBS to induce acute colitis. Staining for DNA with DAPI (blue) and for MAP1LC3 
with Alexa-fluor labeled specific antibodies; (B) MAP1LC3A/B immunohistochemistry staining of 
three archived FFPE samples from patients with an adenocarcinoma of the lung. Different 
MAP1LC3A/B expression levels were visualized using two different antibodies, as indicated. (C) 
MAP1LC3A/B immunohistochemistry staining of FFPE-H1299 NSCLC cells that were either left 
untreated (Ctrl) or treated with everolimus, a selective inhibitor of MTOR activity used to stimulate 
autophagy. Detailed instructions on how the quantification of LC3B dot formation is done can be 
found in [84,86,87]. See abbreviations in the abbreviations section. 
A variety of suppliers provide adequate antibodies that should be evaluated and finely 
calibrated in each cell/tissue and methodological condition to gain an optimal signal/background 
ratio. A nonexhaustive list is given in Table 4. 
Figure 4. Immunofluorescence for MAP1LC3B. (A) Colon tissue sections of a control mouse and a
mouse treated by TNBS to induce acute colitis. Staining for DNA with DAPI (blue) and for MAP1LC3
with Alexa-fluor labeled specific antibodies; (B) MAP1LC3A/B immunohistochemistry staining of three
archived FFPE samples from patients with an adenocarcinoma of the lung. Different MAP1LC3A/B
expression levels were visualized using two different antibodies, as indicated. (C) MAP1LC3A/B
immunohistochemistry staining of FFPE-H1299 NSCLC cells that were either left untreated (Ctrl) or
treated with everolimus, a selective inhibitor of MTOR activity used to stimulate autophagy. Detailed
instructions on how the quantification of LC3B dot formation is done can be found in [84,86,87]. See
abbreviations in the abbreviations section.
Detecting co-localization of key autophagy proteins or post-translational modifications associated
with an active autophagy state might represent new approaches to better describe autophagic activity
in tissue. In addition, the quality of the tissue materials from patients and animals, e.g., the time
from removing the specimen to tissue fixation, is key to adequately assess autophagy. Clinical studies
sometimes rely on quantifying MAP1LC3 staining intensity rather than analyzing MAP1LC3 dot
formation to evaluate autophagic activity in archived patient samples. This is clearly less conclusive and
should be avoided. Analyzing MAP1LC3 punctae formation, although not measuring the autophagic
flux per se, better represents increased autophagic activity (Figure 4B,C) [87]. Improved and new
techniques are critical to enabling autophagy flux analyses in the human tissues.
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Table 4. Non-exhaustive list of MAP1LC3 antibodies.
Antibodies Applications, Conditions 1 Limitations
Polyclonal anti-MAP1LC3B
antibody (#NB600-1384, Novus
Biologicals)
Western blot 1:1000 in 5% (w/v)
non-fat milk, 3h, room
temperature.
For example, ref [84,86,87]
MAP1LC3A cross-reaction
Polyclonal affinity-purified rabbit
anti-MAP1LC3B antibody (#2775;
Cell signaling Technology)
Western blot, 1:1000
Used with human primary cells
(PBMCs, dendritic cells,
monocytes, macrophages), cell
lines.
For example ref [12]
Rabbit anti-MAP1LC3B antibody
(#3868,Cell Signaling)
Immunofluorescence 1:200 in
PBS-1% (w/v) BSA.
Anti-MAP1LC3B antibody
(#M186-3, MBL Inc.)
Western blot 0.5 µg/mL and
immunofluorescence 5 µg/mL in
TBS containing 1% non-fat milk.
Used for example with sciatic
nerves sections from Lewis rats;
with malignant
glioblastoma-derived U-251MG
cells; with mouse spleen and
salivary glands cells; with colonic
cells from mice with colitis
(Figure 4).
For example, ref. [29,30,57]
Monoclonal rabbit
anti-MAP1LC3B antibody, clone
D11 (#3686, Cell Signaling)
Immunofluorescence.
For example ref [84,86,87] See the legend of Figure 4B
Polyclonal affinity-purified rabbit
anti-MAP1LC3A/B antibody
(#4108; Cell signaling Technology)
Immunofluorescence 1:200
dilution.
Used with cell lines.
For example, ref [12]
1 These conditions are routinely used in our respective laboratories. They have to be adapted to each type of
substrate and technique. See abbreviations in the abbreviations section.
5. MAP1LC3-Based Methods Designed for Autophagy In Vivo
A number of approaches have been described to detect MAP1LC3 in living experimental animals.
They are listed in Table 5 with respective performances and merits.
Despite the availability of various approaches for analyzing the autophagy in vivo in experimental
models, and their potential use to screen therapeutic molecules and study the fundamental process of
autophagy, their translation into the clinic remains limited. Further research is necessary to develop
suitable probes that are safer and can be used in humans to analyze autophagy in vivo.
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Table 5. Methods to measure autophagy in vivo 1,2.
Method Advantages Limitations
Transgenic mice expressing
GFP-MAP1LC3 and fluorescence
microscopy
Allow the formation of
autophagosomes to be studied.
Used to study macroautophagy
and mitophagy.
Do not permit the formation of autolysosome
to be studied as GFP loses its fluorescence at
acidic pH in lysosomes. Other transgenic
mice are required [88]
No measurement of autophagic flux.
Cells possess auto-fluorescent punctate
structures such as lipofuscin that is detectable
in the green spectra. Always compare to
non-transgenic control littermates [66].
mCherry-GFP-MAP1LC3 and
mRFP-GFP-MAP1LC3 mouse and
fluorescence microscopy
High time resolution.
Technical difficulty in distinguishing
RFP/GFP double-positive and single
positive punctae.
Lack of performance to measure the basal
autophagic flux.
GFP-MAP1LC3-RFP-LC3∆G
mRNA (injected in animal eggs)
and fluorescence microscopy
Measure the basal (low) and
induced autophagy flux in
embryos and tissues of zebrafish
and mice [70].
1 SBI-0206965 (Adooq Bioscience), a potent and selective inhibitor of ULK1, can be used to inhibit autophagy
in vivo; is given intraperitoneally into mice at 2 mg/kg body weight in DMSO, once per day for 7 days [89];
other autophagy blockers can be used in vivo as control, e.g., CQ/HCQ, NH4Cl, bafilomycin A1 (in certain strict
conditions), colchicine, vinblastine, and the inhibitor of lysosomal enzymes leupeptide [66]. 2 Measurement
of chaperone-mediated autophagy (CMA) activity in vivo has been described [90]. See abbreviations in the
abbreviations section.
6. Conclusions
This short survey clearly identifies the crucial need for developing more performant assays
permitting to screen autophagy regulator molecules in vivo. In view of the lack of suitable techniques
to analyze autophagy flux in vivo in humans, the best possible solution would be to investigate
autophagy flux by using cells derived from the affected organs/tissues of the patients with aberrations
in the autophagy. Alternatively, induced pluripotent stem cell technology (3D tissue cultures or
organoids) could be exploited in order to reprogram human somatic cells to obtain disease-relevant cell
types for the investigations. Genome-wide studies have reported several disease-associated loci and
genes that affect autophagy [4,91]. Though ex vivo, these cells provide an opportunity to investigate
the role of autophagy in the pathogenesis of diseases and to get a clue on if therapeutic molecules that
are deemed beneficial in the animal models could be used in the patients.
It is also important that MAP1LC3-based analyses need to be complemented with lysosomal
function to confirm the intact autophagy process. Though MAP1LC3 analyses indicate the autophagy
process, the functional intactness of lysosomes is critical to complete the process via degradation
of macromolecules and damaged cellular components. In fact, several muscular disorders such
as X-linked myopathy with excessive autophagy, inclusion body myositis (IBM), IBM-associated
with Paget’s disease of the bone, frontotemporal dementia, and amyotrophic lateral sclerosis are
associated with reduced proteolytic activity of lysosomes through enhanced autophagosome biogenesis
was observed [92,93]. This feature has also been observed in lupus settings (Wang and Muller,
unpublished data).
We deliberately focused this article on MAP1LC3-based analyses and macroautophagy. We listed
the different ways of MAP1LC3 quantification in different settings and the arguments pro and against
these measurements (see also Box 1 for recommendation). We emphasized here the importance of
complementing MAP1LC3 autophagy measurements with nonMAP1LC3-based techniques. Other
markers should be systematically followed such as SQSTM1, BECLIN-1, WIPI-1, ATG5/12, ATG14,
ATG16L1, VPS34, LAMP2A, and others if possible, to support the results obtained with MAP1LC3.
It is also important to distinguish the noncanonical autophagy process known as LC3-associated
phagocytosis (LAP) from the canonical autophagy process. LAP and canonical autophagy processes
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do not require hierarchical intervention of all of the ATG proteins [94]. Both pathways do not play the
same functions in cellular homeostasis and physiology, and therefore differentiating both processes can
be highly relevant [95]. Recent studies on monocyte/macrophages revealed that LAP has a significant
role in phenotype differentiation, particularly on the anti-inflammatory phenotype [96]. In addition to
its role in regulating autoimmune response [97], LAP-mediated protective response against hepatic
and systemic inflammation are also documented [98].
As reviewed in this article, biochemical assays, electron microscopy, and light microscopy are useful
in assessing the autophagic process, however, these assays are cell type-, context-, and time-dependent.
Immunologists or cell biologists who have equipped the laboratory with many techniques, should
consider using as many markers possible and also, at least, two independent techniques to confirm the
autophagic process. Autophagic flux analyses are especially recommended. Despite advancements in
the methods to measure autophagy, there is still a lack of completeness, which should be answered
with future developments. Novel methods, both in vitro and especially in vivo, to detect changes in
the autophagy process in living tissues, are particularly awaited. They are decisive to discover and
develop new, more effective drugs that target the autophagy machinery for patient care.
Author Contributions: All authors wrote the manuscript. All authors have read and agreed to the published
version of the manuscript.
Funding: This research was funded by the French Centre National de la Recherche Scientifique, Région Grand-Est
and the FHU ARRIMAGE, the Laboratory of Excellence Medalis (ANR-10-LABX-0034), Initiative of Excellence
(IdEx), Strasbourg University, the University of Strasbourg Institute for Advanced Study (USIAS), and the
Swiss National Science Foundation (31003A_173219 to M.P.T.). M.P.T. and S.M. acknowledge the support of the
TRANSAUTOPHAGY COST Action (CA15138). S.M. also thanks the Club francophone de l’autophagie (CFATG)
and the European Regional Development Fund of the European Union in the framework of the INTERREG V
Upper Rhine program.
Acknowledgments: We thank Sruthi Retnakumar (Strasbourg), Sabina Berezowska (Bern), and Anna M. Schläfli
(Bern) for giving access to the results shown in Figure 4.
Conflicts of Interest: S.M. is co-inventor of CNRS-ImmuPharma patents on P140 peptide; has received research
funds (paid to institution). The other authors declare no conflicts of interest. All declare that the research was
conducted in the absence of any commercial or financial relationships that could be construed as a potential
conflict of interest.
Glossary
Amphisomes
are single-membrane compartment issue from the fusion of autophagosomes
and endosomes
Autolysosomes
are single-membered acidic vesicle formed by the fusion of autophagosome
and lysosome
Autophagosomes
are well discriminated double-membrane vesicles in which intracellular material (incl.
organelles and fragments of organelles) are sequestered and delivered to the lysosome
for degradation
Endosomes are single-membrane compartment formed by the process of endocytosis
Lysosomes
are digestive organelles of the cell, which bear an acidic environment (pH 4.5 to 5.0) to
degrade material via different processes
v-ATPases
are membrane-associated proton pumps, which maintain the acidic environment in
organelles, such as the endosomes, lysosomes, trans-Golgi network, and
secretory granules.
Abbreviations:
AMPK adenosine monophosphate-activated protein kinase
ATG autophagy-related
ATP adenosine triphosphate
Baf A1 bafilomycin A1
BSA bovine serum albumin
LC3-I/-II MAP1LC3-I/-II
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CQ/HCQ chloroquine/hydroxychloroquine
Ctrl control nonsmall
DAPI 4′,6-diamidino-2-phenylindole
DMSO dimethyl sulfoxide
ER endoplasmic reticulum
FFPE formalin-fixed paraffin-embedded
FkBP-12 FK506 binding protein-12 kDa
GAPR-1 Golgi-associated pathogenesis related-1 protein
GFP green fluorescent protein
GFP-MAP1LC3-
RFP-LC3∆G
construct in which the C-terminus of GFP-LC3 is fused to RFP-LC3 protein deleted
from its C-terminal glycine
HSP heat shock protein
LDH lactate dehydrogenase
MAP1LC3 microtubule-associated protein 1A/1B-light chain 3
mRFP monomeric red fluorescent protein
MTOR mechanistic target of rapamycin
MTORC1 mammalian target of rapamycin complex 1
NSCLC nonsmall cell lung cancer
PBMCs peripheral blood mononuclear cells
PBS phosphate-buffered saline
PI3K phosphatidylinositol 3-kinase
PKB/AKT protein kinase B
RFP red fluorescent protein
SAHA suberanilohydroxamic acid
SIRT1 sirtuin 1
TBS Tris-buffered saline
TC trial compound
TNBS 2,4,6 trinitrobenzene sulfonic acid
v-ATPase vacuolar-type H+-ATPase
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